Abstract
Heart failure accounts for more deaths in the United States than any other detrimental human pathology. Recently, repairing the heart after seemingly irreversible injury leading to heart failure appears to have come within reach. Cellular cardiomyoplasty, transplanting viable cell alternatives into the diseased myocardium, has emerged as a promising possible solution. Translating this approach from the laboratory to the clinic, however, has been met with several challenges, leaving many questions unanswered. This review assesses the state of investigation of several progenitor cell sources, including induced pluripotent stem cells, embryonic stem cells, bone marrow stem cells, adipose-derived adult stem cells, amniotic fluid stem cells, skeletal muscle progenitors, induced pluripotent stem cells and cardiac progenitors. Several current roadblocks to maximum success are discussed. These include understanding the need for cardiomyocyte differentiation, appreciating the role of paracrine factors, and addressing the low engraftment rates using current techniques. Tissue engineering strategies to address these obstacles and to help maximize cellular cardiomyoplasty success are reviewed.
Keywords: Progenitor cell, differentiation, paracrine factors, cell delivery, tissue engineering, myocardial infarction
Current Stem Cell Research & Therapy
Title: Lost in Translation: What is Limiting Cardiomyoplasty and Can Tissue Engineering Help?
Volume: 4 Issue: 3
Author(s): David Simpson and Samuel C. Dudley Jr.
Affiliation:
Keywords: Progenitor cell, differentiation, paracrine factors, cell delivery, tissue engineering, myocardial infarction
Abstract: Heart failure accounts for more deaths in the United States than any other detrimental human pathology. Recently, repairing the heart after seemingly irreversible injury leading to heart failure appears to have come within reach. Cellular cardiomyoplasty, transplanting viable cell alternatives into the diseased myocardium, has emerged as a promising possible solution. Translating this approach from the laboratory to the clinic, however, has been met with several challenges, leaving many questions unanswered. This review assesses the state of investigation of several progenitor cell sources, including induced pluripotent stem cells, embryonic stem cells, bone marrow stem cells, adipose-derived adult stem cells, amniotic fluid stem cells, skeletal muscle progenitors, induced pluripotent stem cells and cardiac progenitors. Several current roadblocks to maximum success are discussed. These include understanding the need for cardiomyocyte differentiation, appreciating the role of paracrine factors, and addressing the low engraftment rates using current techniques. Tissue engineering strategies to address these obstacles and to help maximize cellular cardiomyoplasty success are reviewed.
Export Options
About this article
Cite this article as:
Simpson David and Dudley Jr. C. Samuel, Lost in Translation: What is Limiting Cardiomyoplasty and Can Tissue Engineering Help?, Current Stem Cell Research & Therapy 2009; 4 (3) . https://dx.doi.org/10.2174/157488809789057437
DOI https://dx.doi.org/10.2174/157488809789057437 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biomarkers Associated with Bleeding Risk in the Setting of Atrial Fibrillation
Current Medicinal Chemistry Phase II and Pharmacological Study of Oral Docetaxel Plus Cyclosporin A in Anthracycline Pre-Treated Metastatic Breast Cancer
Current Clinical Pharmacology Sealing the Broken Barrier in IBD: Intestinal Permeability, Epithelial Cells and Junctions
Current Drug Targets Polymer-Drug Nanoconjugate – An Innovative Nanomedicine: Challenges and Recent Advancements in Rational Formulation Design for Effective Delivery of Poorly Soluble Drugs
Pharmaceutical Nanotechnology Nitrogen Containing Privileged Structures and their Solid Phase Combinatorial Synthesis
Combinatorial Chemistry & High Throughput Screening Cytochrome P450 Regulation and Drug Biotransformation During Inflammation and Infection
Current Drug Metabolism Vitamin D and Stroke: Promise for Prevention and Better Outcome
Current Vascular Pharmacology Cardiac Surgery and Inflammation: The Inflammatory Response and Strategies to Reduce the Systemic Inflammatory Response Syndrome
Current Cardiology Reviews Reversal of Calcium Dysregulation as Potential Approach for Treating Alzheimer's Disease
Current Alzheimer Research Nutrition Status and Weight Management in Chinese Women
Current Women`s Health Reviews Physiologic Tailoring of Treatment in Resistant Hypertension
Current Cardiology Reviews Meet Our Associate Editor
MicroRNA Targets for Medical Therapy to Limit Abdominal Aortic Aneurysm Progression
Current Drug Targets Comparison of Valvulopathy Risk with Lorcaserin and Phenterminetopiramate for Weight Loss
Current Drug Therapy Peroxisome Proliferator-Activated Receptors and the Control of Fatty Acid Oxidation in Cardiac Hypertrophy
Mini-Reviews in Medicinal Chemistry Possible Links of Age Related Hypertension and Evolution Imposed Features of Heart and Aorta
Current Aging Science Alcohol Induced Hepato Cardiotoxicity and Oxidative Damage in Rats: The Protective Effect of n-butanol Extract of Green Tea (Camellia sinensis (L.) Kuntze)
Cardiovascular & Hematological Disorders-Drug Targets Anti-Inflammatory Actions of the Heme Oxygenase-1 Pathway
Current Pharmaceutical Design Patent Selections
Recent Patents on Medical Imaging Aortic Stenosis, Aortic Regurgitation and Arterial Hypertension
Current Vascular Pharmacology